Loading...
Market
Will regulatory approval be granted for Lundbeck's acquisition of Longboard Pharmaceuticals by the end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Announcements from regulatory bodies or official press releases
Story
Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion at $60/Share, 77% Premium
Oct 14, 2024, 12:13 PM
Lundbeck, a Danish pharmaceutical company, has announced its acquisition of Longboard Pharmaceuticals for $2.6 billion. The deal values Longboard at $60 per share, representing a 77% premium to its volume-weighted average price. This acquisition is expected to significantly enhance Lundbeck's neuroscience pipeline, particularly in the area of neuro-rare treatments, including a Phase 3 drug for Dravet syndrome. The transaction has been unanimously approved by the boards of both companies and is anticipated to close in the fourth quarter of 2024, pending regulatory approvals. Centerview LLC advised on the deal. Longboard's stock surged by over 50% in pre-market trading following the announcement.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
On time (by Q4 2024) • 25%
Delayed to Q1 2025 • 25%
Delayed to Q2 2025 or later • 25%
Deal Cancelled • 25%
Significant enhancement in neuroscience pipeline • 25%
Moderate enhancement • 25%
No significant change • 25%
Negative impact • 25%
Antitrust Concerns • 25%
Financial Discrepancies • 25%
Intellectual Property Issues • 25%
Other • 25%
Regulatory hurdles • 25%
Financing issues • 25%
Shareholder opposition • 25%
Other • 25%
Lundbeck's stock rises over 5% • 25%
Lundbeck's stock falls over 5% • 25%
Longboard's stock remains stable • 25%
Other • 25%
Yes • 50%
No • 50%
